Sanofi and Regeneron's Dupixent approved in Japan for children with asthma

The Japanese Ministry of Health has approved Dupixent for the treatment of bronchial asthma in children aged 6 to 11. This drug, developed by Sanofi and Regeneron, is already used for older patients. The approval is based on phase 3 studies demonstrating a significant reduction in exacerbations and an improvement in lung function. The observed side effects were primarily injection site reactions and a few cases of eosinophilia. This decision could transform the treatment of severe asthma, which significantly impacts the daily lives of young patients. Dupixent is already approved for several other indications.